Biomarkers for Initiating Onsite and Faster Ambulance Stroke Therapies
Biomarkers for Initiating Onsite and Faster Ambulance Stroke Therapies
Stroke is the first cause of death among Spanish women and main cause of disability.
 Reperfusion therapies of the occluded artery remain the only useful approach in acute
 ischemic stroke. However, the efficacy of these strategies is highly time-dependent and due
 to the need of neuroimaging (CT or MRI) to differentiate between ischemic and hemorrhagic
 stroke, impossible to be performed at the pre-hospital level. The investigators aim to set-up
 a point of-care (POC) device to validate a biomarker panel differentiating ischemic and
 hemorrhagic stroke at the pre-hospital level using a blood sample and to validate a second
 biomarker panel for the early identification of patients with large vessel occlusions (LVO),
 which are candidates for mechanical thrombectomy. For that, the investigators will recruit a
 300 patients' cohort with pre-hospital blood samples using available POCs for each of those
 markers.
Inclusion Criteria:

 -  I.1: Patients > 18 years old.

 -  I.2: Stroke code activated by the coordinator centre.

 -  I.3: < 6 hours from symptoms onset. In the case of stroke with uncertain chronology or
 wake-up stroke, the initial time will be considered as the last moment the patient was
 seen fine.

 Exclusion Criteria:

 -  E.1: Prehospital diagnosis different of stroke.

 -  E.2: Impossibility of getting a prehospital blood sample.

 -  E.3: Refusal to provide the informed consent by the patient/relative.